Oklahoma House Bill HB1416

Oklahoma 2026 Regular Session

• Introduced: 2/3/25
• Refer: 2/4/25
• Report Pass: 2/26/25
• Engrossed: 3/4/25
• Refer: 4/1/25

Caption

Non-opioid treatment; terms; preferred drug lists; discretion; drug treatment; United States Food and Drug Administration; coverage; non-opioid drugs; reimbursement; effective date.

Summary

HB1416 creates a new section of Oklahoma law directing insurers that offer group insurance plans for state employees to manage preferred drug lists in a way that does not disadvantage or discourage FDA-approved non-opioid pain treatments relative to opioid or narcotic pain drugs. The bill defines key terms such as “group insurance plan,” “health care prescriber,” “insurer,” and “non-opioid treatment,” and it applies both to coverage decisions made by the plan itself and to drugs provided under pharmacy benefit manager contracts. The measure does not require insurers to prefer non-opioid drugs over opioids, but it does prohibit placing non-opioid pain medications at a coverage disadvantage compared with opioid or narcotic alternatives on the preferred drug list. It also allows preference among drugs within the same category, meaning opioids can still be preferred over other opioids and non-opioids over other non-opioids. The bill is set to take effect November 1, 2025.

Impact

If enacted, HB1416 would add a new statutory requirement in Title 74 governing how insurers structure preferred drug lists for state employee group insurance plans. It would affect insurers, pharmacy benefit managers, and state employee health coverage by limiting formulary design practices that could steer patients away from non-opioid pain treatments. The practical effect is to increase access and coverage parity for FDA-approved non-opioid analgesics in state employee plans, while leaving broader insurer discretion intact within drug classes.

Sentiment

The bill appears to have broad support in the House, passing the Public Health Committee unanimously, then the Health and Human Services Oversight Committee unanimously as amended, and later clearing third reading by a wide margin of 90-7. The voting pattern suggests generally favorable sentiment toward encouraging non-opioid pain treatment options and reducing barriers to their coverage. No committee transcripts were provided, so the available record shows support but not detailed debate.

Contention

The main policy issue is whether insurers should be restricted in how they place non-opioid pain medications on preferred drug lists relative to opioids. Supporters appear to favor protecting access to non-opioid treatments and discouraging opioid-favoring formulary structures, while any opposition likely centers on preserving insurer and pharmacy benefit manager discretion in benefit design and cost management. The bill’s narrow scope also suggests limited contention over whether it mandates preference for non-opioids; it does not, but instead requires parity in coverage treatment.